Akari Therapeutics
AKTX
3 hedge funds and large institutions have $269K invested in Akari Therapeutics in 2015 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 7 closing their positions.
63% less funds holding
Funds holding: 8 → 3 (-5)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
98% less capital invested
Capital invested by funds: $11.5M → $269K (-$11.2M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$100K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$100K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$3.37M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$3.23M |
| 3 |
BC
Broadfin Capital
New York
|
-$2.26M |
| 4 |
SCM
Sio Capital Management
New York
|
-$881K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$211K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $218K | -$50K | -2 | -5% |
|
|
VKH
2
Virtu KCG Holdings
New York
| $26K | +$100K | +4 | New |
|
|
3
Citadel Advisors
Miami,
Florida
| $22K | +$100K | +4 | New |
|
4
Citigroup
New York
| $1K | – | – | – |
|
5
UBS Group
Zurich,
Switzerland
| $1K | – | – | – |
|
6
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
7
Franklin Resources
San Mateo,
California
| – | -$3.37M | -88 | Closed |
|
|
BBA
8
Baker Bros. Advisors
New York
| – | -$3.23M | -84 | Closed |
|
|
SM
9
Sabby Management
Miami Beach,
Florida
| – | -$2.59K | -67 | Closed |
|
|
BC
10
Broadfin Capital
New York
| – | -$2.26M | -59 | Closed |
|
|
SCM
11
Sio Capital Management
New York
| – | -$881K | -23 | Closed |
|
|
DCM
12
DAFNA Capital Management
Los Angeles,
California
| – | -$211K | -5 | Closed |
|
13
HighTower Advisors
Chicago,
Illinois
| – | -$66K | -2 | Closed |
|
|
TRCT
14
Tower Research Capital (TRC)
New York
| – | -$3K | – | – |
|
AKTX Hedge Fund Activity: Q1 2015 in Review
3 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q1 2015, worth a combined $269K — down 98% from $11.5M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of AKTX and 2 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $100K. The largest seller was Franklin Resources, exiting entirely with an estimated $3.37M sold.
- 3 institutional investors held Akari Therapeutics (AKTX) as of Q1 2015, down from 8 in Q4 2014.
- Funds reported $269K of Akari Therapeutics stock for Q1 2015, down 98% quarter-over-quarter.
- 2 funds opened new Akari Therapeutics positions in Q1 2015 and 7 closed out, a net change of -5 holders.
- The largest Akari Therapeutics buyer in Q1 2015 was Citadel Advisors, an estimated $100K added.
- The largest Akari Therapeutics seller in Q1 2015 was Franklin Resources, an estimated $3.37M sold.
Based on aggregated 13F filings for Q1 2015.